Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States

Meletios A Dimopoulos; Αchilles Anagnostopoulos

doi:10.1053/j.seminhematol.2003.09.008

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2004

Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors

Αchilles Anagnostopoulos, Dimitra Gika, George Hamilos, Konstantinos Zervas, Athanasios Zomas, Anastasia Pouli, M.P. Zorzou, Efstathios Kastritis, Nikolaos Anagnostopoulos, Anna Tassidou, Dimitra Anagnostou, Meletios A Dimopoulos

Article2001

Thalidomide and dexamethasone combination for refractory multiple myeloma

Meletios A Dimopoulos, Konstantinos Zervas, G. Kouvatseas, Eleni Galani, Vassiliki Grigoraki, Christos Kiamouris, E. Vervessou, E. Samantas, C Papadimitriou, Olga Economou, Dimitra Gika, Panayiotis Panayiotidis, Ioannis Christakis, Nicolaos Anagnostopoulos

Article2020

Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States

Shaji Kumar, István Májer, Sumeet Panjabi, Rohan Medhekar, Marco Campioni, Meletios A Dimopoulos

Article2009

Treatment of Relapsed/Refractory Multiple Myeloma

Efstathios Kastritis, Antonio Palumbo, Meletios A Dimopoulos

Article2019

Cost-effectiveness of once weekly carfilzomib 70 mg/m<sup>2</sup> plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.

Shaji Kumar, István Májer, Sumeet Panjabi, Jean Malacan, Rohan Medhekar, Marco Campioni, Meletios A Dimopoulos